ArticleNature communications2026
Radiolabeling of oligopeptides by selective hydrogen isotope exchange with deuterium and tritium in aqueous buffers.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Water-Dispersible Ruthenium Nanocatalyst for Carbonyl Reduction With DAngewandte Chemie (International ed. in English) · 2026Article
- Late-stage generation ofNature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Isotopic labeling of organic compounds is crucial for advancements in life sciences and is extensively utilized in drug discovery. While isotopic labeling is widely applied to small molecules, research on isotopically labeled biologics such as peptides, antibodies, or enzymes remains less developed, despite the increasing prevalence of these larger biologics in the pharmaceutical industry as transformative treatments for patients. We report the development of an in situ prepared catalyst for Hydrogen Isotope Exchange reactions with deuterium or tritium gas as the isotope source to selectively label peptides in aqueous solutions. The method requires only low amounts of catalyst and provides the radiolabeled peptide in a single reaction step with sufficient specific activity for biological in-vitro experiments, paving the way for future developments and applications in biological based drugs studies. Furthermore, we have identified a substrate-mediated formation of the active catalytic species, leading to the high selectivity in this late-stage functionalization approach of complex peptide compounds. DFT calculations and NMR studies have identified the intermediate species involved. The reported insights accelerate the access to radiolabeled tracers to understand biological processes, as well as offer future opportunities for highly selective C-H activation and C-C or C-X bond formation to achieve highly selective late-stage functionalization products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.